{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:25:40Z","timestamp":1760059540565,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background: Chronic mitral regurgitation (MR) is categorized into primary and secondary MR (SMR). While primary MR arises from structural abnormalities of the mitral valve apparatus, SMR is a consequence of cardiac remodeling, typically due to heart failure or atrial fibrillation. Management strategies differ significantly, with primary MR requiring direct valvular intervention and SMR necessitating a comprehensive approach incorporating guideline-directed medical therapy (GDMT), revascularization, and resynchronization strategies. The MitraClip, a transcatheter edge-to-edge repair (TEER) device, has emerged as a recommended intervention for symptomatic severe SMR despite optimal GDMT. Objectives: This study aims to evaluate national trends in MitraClip placements in the U.S. from 2016 to 2021 and to assess 90-day readmission events following the procedure. Additionally, we analyze patient and socioeconomic factors associated with heart failure readmissions post-MitraClip placement to optimize patient selection criteria. Methods: The study utilized data from the National Inpatient Sample (NIS) for the years 2016\u20132021 and the National Readmissions Database (NRD) for 2021. Patients who underwent MitraClip placement were identified using ICD-10 code 02UG3JZ. We stratified the population based on demographics, hospital resource utilization, and comorbidities. Index admissions were classified based on the presence or absence of heart failure remissions within 90 days post-procedure. Statistical analyses, including ANOVA and logistic regression, were conducted to identify factors associated with readmissions. Results: MitraClip utilization demonstrated a rising trend from 2016 to 2021, with total annual procedures increasing from 869 to 2488. Mean patient age remained stable at 76\u201379 years, with a nearly equal sex distribution. In-hospital mortality remained low (1\u20133%) throughout the study period. A steady increase in hospital charges was observed, alongside a decline in the mean length of stay. Analysis of 4918 index admissions for MitraClip placement in 2021 identified 780 total readmissions within 90 days, with 206 (26.4%) attributed to heart failure. Factors significantly associated with increased risk of heart failure readmissions included atrial fibrillation (OR 3.77, CI 1.82\u20134.23), pulmonary hypertension (OR 3.96, CI 1.49\u20135.55), and chronic lung disease (OR 1.91, CI 1.32\u20132.77). Conclusions: The increasing adoption of MitraClip underscores its growing role in managing SMR. However, heart failure readmissions remain a significant concern. Identifying high-risk patient profiles can refine selection criteria and enhance post-procedural management strategies to improve clinical outcomes. Further research is needed to optimize patient selection and refine risk stratification for MitraClip interventions.<\/jats:p>","DOI":"10.3390\/medsci13030081","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T08:13:56Z","timestamp":1750407236000},"page":"81","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in MitraClip Placements and Predictors of 90-Day Heart Failure Rehospitalization: A Nationwide Analysis"],"prefix":"10.3390","volume":"13","author":[{"given":"Vivek Joseph","family":"Varughese","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of South Carolina, Prisma Health, Columbia, SC 29201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh","family":"Krishnan Nagesh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seetharamaprasad","family":"Madala","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of South Carolina, Prisma Health, Columbia, SC 29201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Bhuju","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carra","family":"Lyons","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of South Carolina, Prisma Health, Columbia, SC 29201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simcha","family":"Weissman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Atoot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Vacca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of South Carolina, Prisma Health, Columbia, SC 29201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budoor","family":"Alqinai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1056\/NEJMcp1903331","article-title":"Secondary Mitral Regurgitation","volume":"383","author":"Mack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(05)70233-6","article-title":"Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): A randomised trial","volume":"365","author":"Mendelow","year":"2005","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ccd.21522","article-title":"The COURAGE trial in perspective","volume":"72","author":"Prasad","year":"2008","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jacc.2022.08.803","article-title":"Hospitalizations and Mortality in Patients with Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial","volume":"80","author":"Giustino","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2021.11.027","article-title":"Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: Insights from the multi-center MITRA-TUNE registry","volume":"349","author":"Testa","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ejhf.3286","article-title":"Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials","volume":"26","author":"Anker","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.jacc.2015.10.018","article-title":"Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II","volume":"66","author":"Feldman","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","unstructured":"(2025, June 10). ICD-10-CM|Classification of Diseases, Functioning, and Disability|CDC. The Web\u2019s Free 2025 ICD-10-CM\/PCS Medical Coding Reference. Available online: https:\/\/www.icd10data.com\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","article-title":"Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials","volume":"12","author":"Grayburn","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamacardio.2020.7200","article-title":"Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Investigators. Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio with Transcatheter Mitral Valve Repair Outcomes: A Secondary Analysis of the COAPT Trial","volume":"6","author":"Lindenfeld","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jcin.2018.12.006","article-title":"Diagnostic Value of 3-Dimensional Vena Contracta Area for the Quantification of Residual Mitral Regurgitation After MitraClip Procedure","volume":"12","author":"Avenatti","year":"2019","journal-title":"J. Am. Coll. Cardiol. Interv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jtcvs.2019.12.097","article-title":"Trends in MitraClip, mitral valve repair, and mitral valve replacement from 2000 to 2016","volume":"162","author":"Zhou","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4244\/EIJ-D-18-00961","article-title":"Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: Five-year German national patient sample including 13,575 implants","volume":"14","author":"Hobohm","year":"2019","journal-title":"EuroIntervention"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ejhf.1289","article-title":"Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation","volume":"21","author":"Seeger","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Polimeni, A., Albanese, M., Salerno, N., Aquila, I., Sabatino, J., Sorrentino, S., Leo, I., Cacia, M., Signorile, V., and Mongiardo, A. (2020). Predictors of outcomes in patients with mitral regurgitation undergoing percutaneous valve repair. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-74407-z"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jcmg.2018.01.009","article-title":"Mitral Valve Regurgitation in the Contemporary Era: Insights into Diagnosis, Management, and Future Directions","volume":"11","author":"Reddy","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10741-020-10051-z","article-title":"Impact of atrial fibrillation on the outcomes of transcatheter mitral valve repair using MitraClip: A systematic review and meta-analysis","volume":"26","author":"Shah","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e010300","DOI":"10.1161\/CIRCINTERVENTIONS.120.010300","article-title":"Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial","volume":"14","author":"Gertz","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jcin.2020.09.023","article-title":"Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation: The COAPT Trial","volume":"13","author":"Saxon","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ejhf.864","article-title":"Implication of pulmonary hypertension in patients undergoing MitraClip therapy: Results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"20","author":"Tigges","year":"2018","journal-title":"Eur. J. Heart Fail."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:44Z","timestamp":1760032544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/13\/3\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medsci13030081"],"URL":"https:\/\/doi.org\/10.3390\/medsci13030081","relation":{},"ISSN":["2076-3271"],"issn-type":[{"type":"electronic","value":"2076-3271"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}